Principal Financial Group’s Cogent Biosciences COGT Stock Holding History

Principal Financial Group’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.23M	Sell	83,944 -27,862	-25%	-$1.03M	﹤0.01%	1743
2025 Q4	$3.97M	Sell	111,806 -160,654	-59%	-$4.52M	﹤0.01%	1692
2025 Q3	$3.91M	Buy	+272,460	New	+$3.23M	﹤0.01%	1674
2024 Q3	–	Sell	-16,211	Closed	-$137K	–	2264
2024 Q2	$137K	Sell	16,211 -3,704	-19%	-$28.1K	﹤0.01%	2190
2024 Q1	$134K	Sell	19,915 -228	-1%	-$1.41K	﹤0.01%	2239
2023 Q4	$118K	Sell	20,143 -1,124	-5%	-$8.61K	﹤0.01%	2246
2023 Q3	$207K	Buy	21,267 +2,803	+15%	+$33.2K	﹤0.01%	2160
2023 Q2	$219K	Buy	18,464 +1,379	+8%	+$15.8K	﹤0.01%	2159
2023 Q1	$184K	Buy	17,085 +2,505	+17%	+$32K	﹤0.01%	2196
2022 Q4	$169K	Buy	+14,580	New	+$181K	﹤0.01%	2225

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Principal Financial Group's COGT Position: Q1 2026 in Review

Principal Financial Group reduced its Cogent Biosciences (COGT) stake by 25% in Q1 2026, selling an estimated $1.03M and leaving 83,944 shares worth $3.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Principal Financial Group first reported a position in COGT in Q4 2022 and has held it in 10 quarters since. The position peaked at $3.97M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Principal Financial Group held 83,944 shares of Cogent Biosciences worth $3.23M as of Q1 2026.
Principal Financial Group sold 27,862 Cogent Biosciences shares in Q1 2026, an estimated $1.03M.
Cogent Biosciences made up ﹤0.01% of Principal Financial Group's portfolio in Q1 2026, its #1743 holding.
Principal Financial Group first reported a position in Cogent Biosciences in Q4 2022 and has held it in 10 quarters since.
Principal Financial Group's Cogent Biosciences position peaked at $3.97M in Q4 2025.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.